S. Matsuoka, et al. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase Science, 282 (1998), pp. 1893-1897 N.H. Chehab, et al. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53 Genes Dev., 14 (2000), pp. 278-288 D.W. Bell, et al. Heterozygous germ line hCHK2 mutations in Li–Fraumeni syndrome Science, 286 (1999), pp. 2528-2531 K. Schneider, et al. Li–Fraumeni syndrome GeneReviews (1999) Published online January 19, 1999 https://www.ncbi.nlm.nih.gov/books/NBK1311/ K.A. McBride, et al. Li–Fraumeni syndrome: cancer risk assessment and clinical management Nat. Rev. Clin. Oncol., 11 (2014), pp. 260-271 Breast Cancer Association Consortium, et al. Breast cancer risk genes – association analysis in more than 113,000 women N. Engl. J. Med., 384 (2021), pp. 428-439 F.J. Couch, et al. Associations between cancer predisposition testing panel genes and breast cancer JAMA Oncol., 3 (2017), pp. 1190-1196 B. Decker, et al. Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks J. Med. Genet., 54 (2017), pp. 7327-7341 J. Hauke, et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer Cancer Med., 7 (2018), pp. 1349-1358 H. Meijers-Heijboer, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations Nat. Genet., 31 (2002), pp. 555-559 M. Weischer, et al. Increased risk of breast cancer associated with CHEK2*1100delC J. Clin. Oncol., 25 (2007), pp. 57-63 C. Cybulski, et al. CHEK2 is a multiorgan cancer susceptibility gene Am. J. Hum. Genet., 75 (2004), pp. 1131-1135 L. Stolarova, et al. CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate Cells, 9 (2020), p. 2675 M.J. Landrum, et al. ClinVar: public archive of relationships among sequence variation and human phenotype Nucleic Acids Res., 42 (2014), pp. D980-D985 S.E. Brnich, et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework Genome Med, 12 (2019), p. 3 D.W. Bell, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts Int. J. Cancer, 121 (2007), pp. 2661-2667 R. Boonen, et al. Functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk Cancer Res., 82 (2022), pp. 615-631 R. Chrisanthar, et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer PLoS One, 3 (2008), Article e3062 R. Cuella-Martin, et al. Functional interrogation of DNA damage response variants with base editing screens Cell, 184 (2021), pp. 1081-1097 A. Delimitsou, et al. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system Hum. Mutat., 40 (2019), pp. 631-648 J. Falck, et al. The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis Nature, 410 (2001), pp. 842-847 P. Kleiblova, et al. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer Int. J. Cancer, 145 (2019), pp. 1782-1797 S.B. Lee, et al. Destabilization of CHK2 by a missense mutation associated with Li–Fraumeni Syndrome Cancer Res., 61 (2001), pp. 8062-8067 W. Roeb, et al. Response to DNA damage of CHEK2 missense mutations in familial breast cancer Hum. Mol. Genet., 21 (2012), pp. 2738-2744 A. Shaag, et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population Hum. Mol. Genet., 14 (2005), pp. 555-563 M.D. Tischkowitz, et al. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer N. Wang, et al. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk Oncogene, 34 (2015), pp. 5198-5205 X. Wu, et al. Characterization of tumor-associated Chk2 mutations J. Biol. Chem., 276 (2001), pp. 2971-2974 J. Ahn, et al. The Chk2 protein kinase DNA Repair (Amst), 3 (2004), pp. 1039-1047 J. Bartek, J. Lukas Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell, 3 (2003), pp. 421-429 M.B. Kastan, J. Bartek Cell-cycle checkpoints and cancer Nature, 432 (2004), pp. 316-323 J. Li, et al. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2 Mol. Cell, 9 (2002), pp. 1045-1054 J. Zhang, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair Mol. Cell. Biol., 24 (2004), pp. 708-718 C. Hu, et al. Roles of Kruppel-associated box (KRAB)-associated co-repressor KAP1 Ser-473 phosphorylation in DNA damage response J. Biol. Chem., 287 (2012), pp. 18937-18952 M.C. Lanz, et al. DNA damage kinase signaling: checkpoint and repair at 30 years EMBO J., 38 (2019), Article e101801 X. Zhao, et al. The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage EMBO J., 20 (2001), pp. 3544-3553